SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer

Given the pivotal role of epidermal growth factor receptor (EGFR) inhibitors in advanced EGFR-mutant non-small-cell lung cancer (NSCLC), we tested adjuvant erlotinib in patients with EGFR-mutant early-stage NSCLC. In this open-label phase II trial, patients with resected stage IA to IIIA (7 edition...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2019-01, Vol.37 (2), p.97-104
Hauptverfasser:	Pennell, Nathan A, Neal, Joel W, Chaft, Jamie E, Azzoli, Christopher G, Jänne, Pasi A, Govindan, Ramaswamy, Evans, Tracey L, Costa, Daniel B, Wakelee, Heather A, Heist, Rebecca S, Shapiro, Marc A, Muzikansky, Alona, Murthy, Sudish, Lanuti, Michael, Rusch, Valerie W, Kris, Mark G, Sequist, Lecia V
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - enzymology Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Chemotherapy, Adjuvant Disease-Free Survival ErbB Receptors - genetics Erlotinib Hydrochloride - therapeutic use Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - enzymology Lung Neoplasms - genetics Lung Neoplasms - pathology Male Middle Aged Mutation Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - enzymology Neoplasm Recurrence, Local - genetics Neoplasm Recurrence, Local - pathology Neoplasm Staging ORIGINAL REPORTS Protein Kinase Inhibitors - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!